Sehe ich ähnlich wie Scooper. Der Zulassungsprozess in UK und Indien nimmt Fahrt auf und ich fände es schwer abzuschätzen wann sie letzlich kommt...Wäre mir nach der langen Zeit des Wartens zu riskant den Zug dann doch zu verpassen, zumal der Anstieg dann rasant verlaufen sollte. Aber das ist nur meine Meinung.
will das Feld nicht den Chinesen in der Region überlassen und schnellstmöglich Nachbarländer mit Impfstoff versorgen, um sich geo - politisch zu positionieren. Spielt uns in die Hände und wird sicher auch die Unterstützung der USA erfahren.
Novavax is expected to receive authorization from the EMA in October. And the pharmacist has already specified to this newspaper that she was prepared to start sending doses as soon as she received the 'ok' from the agency.
sehr konservativ. Ich denke durch Euphorie und Hype werden wir höher steigen, einfach weil viele noch auf den Zug mit aufspringen wollen. Und bei Robin Hood stehen wir ja bereits in den Top 5,da kann schnell mehr draus werden... Nun ja, aber wie immer gilt: erstmal muss geliefert werden, sonst wird das alles nix...
Novavax and Serum Institute of India Announce Submission to World Health Organization for Emergency Use Listing of Novavax' COVID-19 Vaccine
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, with its partner, Serum Institute of India Pvt. Ltd. (SII), today announced a regulatory submission to the World Health Organization (WHO) for emergency use listing (EUL) of Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M adjuvant. The submission to WHO is based on the companies' previous regulatory submission to the Drugs Controller General of India (DCGI).
"Today's submission of our protein-based COVID-19 vaccine to WHO for emergency use listing is a significant step on the path to accelerating access and more equitable distribution to countries in great need around the world," said Stanley C. Erck, President and Chief Executive Officer, Novavax. "It represents another major milestone in Novavax' transformation into a commercial global vaccine company and reinforces the value of global collaboration and need for multiple approaches to help control the pandemic."
The grant of EUL by the WHO is a prerequisite for exports to numerous countries participating in the COVAX Facility, which was established to allocate and distribute vaccines equitably to participating countries and economies. In addition to the submission for WHO EUL, SII and Novavax last month completed the submission of modules required by regulatory agencies in India, Indonesia and the Philippines for the initiation of review of the vaccine, including preclinical, clinical, and chemistry, manufacturing and controls (CMC) data.
Thread abonnieren
